- •CONTENTS
- •Contributors
- •Preface
- •I Components of Angiogenic Cascades
- •1. Introduction and Historical Perspective
- •2. The Semaphorins
- •3. The Plexin Receptor Family
- •4. The Neuropilins
- •5. Vascular Endothelial Growth Factors and Their Receptors
- •6. Signal Transduction by Neuropilins
- •7. The Role of the Neuropilins in the Regulation of Vasculogenesis and Angiogenesis
- •8. Modulation of Angiogenesis by Semaphorins that Bind Directly to Plexins
- •Acknowledgments
- •References
- •1. Introduction
- •1.1. Eph receptor domain structure
- •1.2. The ephrin domain structure
- •2. Effects on Vascular Cell Behavior and Signaling Pathways
- •2.1. Ephrin-A1 and EphA2
- •2.2. Ephrin-A1 and EphA4
- •2.3. Ephrin-B and EphB
- •2.3.1. EphB forward signaling
- •2.3.2. Ephrin-B reverse signaling
- •2.4. Crosstalk with other angiogenic pathways
- •3. Endothelial Cell Fate
- •4. Angiogenic Remodeling of Embryonic Blood Vessels
- •4.1. Ephrin-A1 and EphA receptors
- •4.2. EphB4 and Ephrin-B2
- •4.3. Other EphB receptors and Ephrin-Bs
- •5. Lymphatic Vessels
- •6. Adult Vasculature
- •6.1. Quiescent vasculature
- •6.2. Physiological angiogenesis
- •6.3. Inflammation and wound healing
- •6.4. Tumor angiogenesis
- •6.4.1. Ephrin-A1 and EphA2
- •6.4.2. Ephrin-B2 and EphB4
- •8. Perspectives
- •Acknowledgments
- •References
- •1. Introduction
- •2. Molecular Mechanisms
- •3. Role in Vascular Development
- •4. FGFs in Tumor Angiogenesis
- •5. Role of FGFs in Developmental and Tumor Lymphangiogenesis
- •7. Conclusion
- •Acknowledgments
- •References
- •1. The NPY System
- •2. NPY as a Growth Factor for Vascular Cells
- •3. DPPIV: A Molecular Switch of the NPY Angiogenic System
- •4. Downstream Mediators of NPY Actions
- •5. NPY in Revascularization of Ischemic Tissues
- •6. NPY in Wound Healing
- •7. NPY in Adipose Tissue Growth and Obesity
- •8. NPY in Retinopathy
- •10. NPY in Tumor Angiogenesis
- •11. NPY-Mediated Angiogenesis and Neurogenesis
- •References
- •1. Introduction
- •2. Historical Perspective
- •3.1. The HSPG core proteins
- •3.2. The structure of the HS chain
- •3.3. The biosynthesis of HS
- •3.4. The post-synthetic processing of HSPGs
- •4. Evolution of HSPGs
- •5. HSPGs in Development
- •6. HSPG Modulation of Ligand-Receptor Interactions
- •6.2. HSPG co-receptors confer unique regulatory properties
- •6.2.1. Co-receptors engender stoichiometric control of signaling
- •6.2.2. The effects of glycanation
- •6.2.3. HS sequence motifs regulate signaling
- •7. HSPGs Enable Global Control of EC Phenotype
- •8. Future Therapeutic Directions
- •9. Conclusions
- •References
- •II Angiogenic Regulators
- •1. Introduction: Blood Vessels and Nerves Use Similar Guidance Cues
- •2. Semaphorin Signaling
- •2.1. Neuropilins
- •2.2. Plexins
- •3. Ephrins and Eph Signaling
- •3.1. Forward signaling
- •3.2. Reverse signaling
- •4. Netrin and Slit Signaling
- •5. Open Questions
- •References
- •1. Oxygen Homeostasis: Phylogeny, Ontogeny, Physiology, and Pathobiology
- •5. Control of Angiogenesis and Arteriogenesis by HIF-1
- •6. Control of Tumor Angiogenesis by HIF-1
- •References
- •1. Introduction
- •2. Reactive Oxygen Species (ROS) in the Vasculature
- •3. ROS and Angiogenesis
- •4. NAD(P)H Oxidase: A Major Source of ROS in the Vasculature
- •5. Role of NAD(P)H Oxidase in Angiogenesis
- •6. ROS as Signaling Molecules in Angiogenesis
- •8. Conclusion
- •References
- •1. Introduction
- •2. Assessing Coronary Angiogenesis and Arteriogenesis
- •3. Pressure Overload-Induced Hypertrophy
- •4. Volume Overload-Induced Cardiac Hypertrophy
- •5. Thyroxine-Induced Hypertrophy
- •6. Hypoxia-Induced Hypertrophy
- •7. Exercise-Induced Hypertrophy
- •8. Myocardial Infarction-Induced Hypertrophy
- •9. Modulators of Angiogenesis During Hypertrophy
- •10. Stimuli of Angiogenesis During Hypertrophy
- •11. Summary
- •References
- •1. Introduction
- •2. Coronary Resistance
- •3. Regulation of Coronary Microvascular Tone
- •3.1. Intrinsic and extrinsic vasomotor control
- •3.2. Role of the endothelium
- •3.3. Role of metabolism and autoregulation
- •3.4. Flow-induced dilation
- •3.5. Neurohumoral influence on microcirculation
- •3.6. Intrinsic myogenic tone
- •3.7. Impact of extravascular and humoral factors on the coronary microcirculation
- •3.8. Role of venules in coronary resistance
- •4. Endothelial Factors in Vascular Growth and Response to Injury
- •5. Impact of Disease States on Coronary Circulation
- •6. The Coronary Microcirculation in Hypertophic States
- •7. Summary
- •References
- •III Clinical Applications
- •1. Kinase Inhibition and Tumor Angiogenesis
- •2. Major Angiogenesis Factors and Receptors
- •2.1. VEGF signaling
- •3. Further Angiogenesis-Related Signaling
- •4. Need for Selectivity of Anti-Angiogenic Kinase Inhibitors
- •5. Kinase Inhibitors in Clinical Development
- •5.1. BAY 43-9006 (Sorafenib)
- •5.2. PTK/ZK (Vatalanib)
- •5.3. SU11248 (Sunitinib)
- •5.9. BIBF 1120
- •5.10. Chir-258
- •5.12. SU5416 (Semaxinib)
- •6. Challenges and Future Directions
- •Acknowledgments
- •References
- •1. Introduction
- •2. Concepts and Rationales
- •3. Strategy
- •4. Clinical Trials
- •4.1. Growth factor-based, angiogenic approach
- •4.2. Cell therapy-based, vasculogenic and paracrine approach
- •5. Issues Regarding Current Strategy
- •5.1. Choice of biological agent
- •5.2. Pharmacokinetics and delivery mode
- •5.3. Monitoring of neovascularization
- •5.4. Study design
- •6. Emerging Concepts of Therapeutic Angiogenesis
- •6.1. Neovascularization responsiveness
- •6.2. Genetic determination of neovascularization
- •7. Future Prospective
- •8. Summary
- •References
- •1. Hepatocyte Growth Factor in Cardiovascular System
- •2. HGF Signaling in Endothelial Cells
- •3. Angiogenic Therapy for Ischemic Peripheral Arterial Diseases
- •4. Clinical Trial in PAD
- •5. HGF Gene Therapy for Myocardial Ischemia
- •6. HGF Gene Therapy for Restenosis After Angioplasty
- •7. Next Five Years Perspective — Future Direction of HGF Therapy
- •Acknowledgments
- •References
- •1. Endothelial Nitric Oxide in Health and Disease
- •1.1. Nitric oxide synthases
- •1.2. Physiological role of endothelial NO (“EDNO”)
- •1.3. Endothelial NO-deficiency in cardiovascular diseases
- •1.4. Therapeutic restoration of endothelial NO production in cardiovascular diseases
- •2. Nitric Oxide and Angiogenesis
- •2.2. Tumor angiogenesis and NO
- •2.3. Evidence in cultured endothelial cells and in rabbit cornea
- •2.4. Role of NO in post-ischemic revascularization
- •2.6. Molecular mechanisms
- •3. NOS Gene Transfer
- •3.1. Gene delivery vectors
- •3.2. NOS-III gene transfer
- •3.3. NOS-II gene transfer
- •4.1. Impaired angiogenesis and arteriogenesis in patients with critical limb ischemia
- •4.2.1. NOS-III-KO mice
- •4.2.2. NOS-III transgenic mice
- •4.2.3. Wild-type NOS-III gene transfer in normal rats
- •4.5.1. Plasmid delivery of the NOS1177D gene
- •4.5.2. Adenoviral delivery of the NOS1179D gene
- •6. Conclusions
- •Acknowledgments
- •References
- •Index
Modulation of Growth Factor Signaling by Heparan Sulfate Proteoglycans |
123 |
The functional diversity of HS began to emerge in the 1970s when the first of numerous heparin/HS-binding proteins were discovered. The groups of Klagsbrun and Folkman, in the early 1980s, championed the use of heparin affinity chromatography to purify EC mitogens.14 This application was a major trigger of investigations into HS-mediated signaling by heparin-binding growth factors, which continue to the present.
3.The Structure, Synthesis, and Post-Synthetic Modification of HSPGs
3.1. The HSPG core proteins
There are multiple HSPG core proteins which contribute to the broad functional repertoire of these hybrid molecules (Fig.1A). Table 2 lists the major vertebrate HSPGs and indicates which are known to exhibit expression in ECs. Some core proteins carry two types of GAG chains — HS and chondroitin sulfate (CS); whereas others exclusively bear HS chains. The major carriers of non-surface bound HS in the extracellular matrix appear to be agrin, perlecan, and collagen XVIII (reviewed in Refs. 11 and 15). Most cell surface HS is carried by glypicans, a family of at least six homologous glycophosphatidyl-inositol (GPI)- anchored proteins, syndecans and four related transmembrane proteins. However, a variety of additional integral membrane proteins, such as betaglycan and splice variants of CD44, are considered as “part-time” proteoglycans because they occasionally bear HS chains. ECs are presently known to express at least 11 distinct HSPG core proteins (Table 2). Specialized features of a given HSPG core protein can: (1) provide direct interactions with cytoskeletal and/or signaling components, (2) define localization to intracellular or extracellular compartments, and (3) allow for cellular internalization, recycling, or transcellular transport (reviewed in Refs. 11, 16 and 17). Thus, the multiplicity of core proteins does not merely reflect redundancy but rather amplifies functional diversity. The core protein together with its associated cellular machinery constitute a platform of such profound utility
124 N. W. Shworak
Fig. 1. Major HSPGs. (A) Major HSPGs of ECs. The EC cell surface and basement membrane are schematically depicted showing a major representative of an integral membrane (syndecan-4), a GPI-linked (glypican-1), and an extracellular (perlecan) HSPG. Syndecan-4 is presented as carrying two HS (unbroken line) and one CS (dotted line) chains, but can bear multiple permutations of these GAGs. (B) The structure of an HS disaccharide repeat. The same repeated disaccharide occurs in both HS and heparin. Remodeling of the glucosamine can involve addition of sulfates to the C3 or C6 positions. Furthermore, the N-acetyl group can be replaced with either a sulfate group or a proton (which generates a free amino group). The uronic acid can be remodeled by adding a sulfate at C2, or by epimerization at C5, which converts glucuronic acid (only C5 region shown) to iduronic acid.
that almost all eukaryotic tissues and cells employ HSPGs in multiple roles.
3.2. The structure of the HS chain
Apart from the multiplicity of core proteins, the HS component of HSPGs further amplifies their complexity and functional diversity. HS is a heterogeneous linear polysaccharide consisting of a repeated disaccharide unit of glucuronic or iduronic acid alternating with glucosamine [hexuronic acid β1→4 N-acetylglucosamine (GlcNAc) α1→4], that is partially decorated with N- and various O-sulfate groups (Fig.1B). The specific arrangement of the sulfate moieties, in large part, gives rise to distinct binding motifs that interact with an increasingly expansive list
Modulation of Growth Factor Signaling by Heparan Sulfate Proteoglycans |
125 |
Table 2.. HSPG core proteins (derived from Refs. 11 and 15).
|
Endothelial |
GAG type |
|
Core proteins |
expression |
(No. of chains) |
Key features |
|
known |
|
|
|
|
|
|
I. Extracellular matrix |
|
|
|
Agrin |
+ |
HS (3) |
|
Perlecan |
+ |
HS/CS (3) |
Large multidomain |
|
|
|
protein |
Testican |
+ |
HS/CS (2) |
|
Type XVIII collagen |
+ |
HS/CS (3) |
Cleavage product is |
|
|
|
endostatin |
II. Cell surface |
|
|
|
Glypican family |
|
|
GPI linked |
Glypican-1 |
+ |
HS (3) |
|
Glypican-2 |
|
HS |
|
Glypican-3 |
|
HS |
|
Glypican-4 |
|
HS |
|
Glypican-5 |
|
HS |
|
Glypican-6 |
|
HS |
|
Syndecan family |
|
|
Type I integral |
|
|
|
membrane proteins |
Syndecan-1 |
+ |
HS/CS (3–5) |
|
Syndecan-2 |
+ |
HS/CS (3) |
|
Syndecan-3 |
|
HS/CS (3–5) |
|
Syndecan-4 |
+ |
HS/CS (3) |
|
Betaglycan |
+ |
HS/CS |
Part-time proteoglycan |
CD44 |
+ |
HS/CS |
Part-time proteoglycan |
FGFR2 |
+ |
HS/CS (1) |
Splice variants |
|
|
|
containing the |
|
|
|
“acid box” |
|
|
|
|
of protein effectors (Table 1).12,18,19 The HS chains are quite long ( 40– 80 nm) and range from 100 to 200 disaccharide units, respectively. Each chain is internally repetitive, containing short blocks of minimal sulfation alternating with blocks of highly sulfated motifs (reviewed in Refs. 11, 16 and 17). Multiple copies of different ligand binding motifs can occur on a single HS chain;20 consequently, HS is exquisitely suited to
126 N. W. Shworak
function as a template for the assembly of multimolecular complexes, such as signaling complexes.
3.3. The biosynthesis of HS
HS synthesis occurs in the Golgi apparatus and involves an extensive series of post-translational modifications (Fig. 2). First, UDP-linked sugars are employed as substrates for polymerizing the HS chain. Then, this backbone is remodeled (largely by sulfotransferases) to create distinct HS motifs. HS sulfotransferases decorate the chain with critically
Fig. 2. HS synthesis. Schematically depicted are the major steps of HS synthesis and their involved co-factors and enzymes. This process is relatively ordered and creates distinct sequence motifs. The early biosynthetic reactions create the minimal sequence required to bind an FGF2 monomer. Conversely, generation of the antithrombin (AT)- binding site requires additional later modification reactions. The very rare 3-O-sulfate moiety is indicated by . Not shown are structures generated by gD-type HS3ST enzymes.
Modulation of Growth Factor Signaling by Heparan Sulfate Proteoglycans |
127 |
positioned sulfate groups by transferring a sulfuryl group from the universal “sulfate” donor 3 phosphoadensosine-5 -phosophosulfate (PAPS) (reviewed in Ref. 15). Although many functions are conveyed by core proteins, they do not play a substantial role in defining the types of HS motifs that occur upon their HS chains.21 Rather, the sequencespecific properties of the various modification enzymes is the critical factor that dictates the production of specific motifs.
Synthesis begins by the assembly of a short linkage tetrasaccharide at defined serine residues of the core proteins (Fig. 2). This step initiates both HS and CS synthesis, which explains why many HSPGs can also carry CS chains. CS exhibits different biological activities than HS due to its distinct structure; CS chains, compared to HS, contain galactosamine instead of GlcNAc, are sulfated in some distinct positions and are shorter. Commitment of the primed structure specifically down the HS pathway is determined by the addition of a GlcNAc residue by either EXTL2 or EXTL3, which are distinct isoforms of GlcNAc transferase I. Conversely, addition of a galactosamine residue triggers CS synthesis. The HS backbone is then polymerized by the simultaneous action of enzymes from the genes EXT1 and EXT2 (reviewed in Refs. 12 and 13).
The copolymer backbone is then remodeled by a semi-ordered series of reactions, which generate distinct HS motifs. First, the bifunctional enzyme HS N-deacetylase/N-sulfotransferase (NDST) deacetylates and N-sulfates subsets of N-acetylglucosamine residues.22,23 Occasional residues escape sulfation, which results in a free amino group. Blocks containing a high density of N-sulfated glucosamine are then preferential substrates for the subsequent, less frequent modification reactions. The HS C5 epimerase transforms occasional glucuronic acid residues into iduronic acid.24,25 The HS 2-sulfotransferase (HS2ST) next produces 2-O-sulfated iduronic acid or to a much lesser degree 2-O-sulfated glucuronic acid.26,27 Occasional glucosamine residues undergo 6-O- sulfation by HS 6-O-sulfotransferase (HS6ST).28 “Late” modification also includes the generation of 3-O-sulfated glucosamine by HS 3-O- sulfotransferase (HS3ST, also known as 3OST).21,29−31
The NDST, HS6ST and HS3ST enzymes have multiple isozymes encoded by distinct genes. This multiplicity serves two purposes. First, multiple isoforms allow for cell type-specific production of distinct HS
